1
|
Olson AP, Schrage BR, Islam MF, Fletcher LS, Verich F, Dierolf MA, Aluicio-Sarduy E, Becker KV, Driscoll DM, Girish N, Simms ME, Kertesz V, White FD, Boros E, Ivanov AS, Engle JW, Thiele NA. Towards the Stable Chelation of Radioantimony(V) for Targeted Auger Theranostics. Angew Chem Int Ed Engl 2025; 64:e202423878. [PMID: 39878457 DOI: 10.1002/anie.202423878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2024] [Revised: 01/28/2025] [Accepted: 01/29/2025] [Indexed: 01/31/2025]
Abstract
Antimony-119 (119Sb) is one of the most attractive Auger-electron emitters identified to date, but it remains practically unexplored for targeted radiotherapy because no chelators have been identified to stably bind this metalloid in vivo. In a departure from current studies focused on chelator development for Sb(III), we explore the chelation chemistry of Sb(V) using the tris-catecholate ligand TREN-CAM. Through a combination of radiolabeling, spectroscopic, solid-state, and computational studies, the radiochemistry and structural chemistry of TREN-CAM with 1XX/natSb(V) were established. The resulting [1XXSb]Sb-TREN-CAM complex remained intact for several days in human serum, signifying high stability under biological conditions. Finally, the first in vivo single photon emission computed tomography and positron emission tomography imaging studies were carried out using 117Sb, the diagnostic analogue of 119Sb. These studies revealed marked differences in the uptake and distribution of activity in mice administered unchelated [117Sb]Sb(OH)6 - versus [117Sb]Sb-TREN-CAM, suggesting that 117Sb is largely retained by TREN-CAM over the time course of the study. Collectively, these findings demonstrate the most physiologically stable complex of no-carrier-added 1XXSb yet reported, offering new promise for the clinical implementation of radioantimony in nuclear medicine. Our results also establish the feasibility of 117Sb as an elementally matched partner to 119Sb for theranostic applications.
Collapse
Affiliation(s)
- Aeli P Olson
- Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, 53705, United States
| | - Briana R Schrage
- Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee, 37831, United States
| | - Md Faizul Islam
- Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee, 37831, United States
| | - Lesta S Fletcher
- Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee, 37831, United States
| | - Francesca Verich
- Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, 53705, United States
| | - Morgan A Dierolf
- Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin, 53705, United States
| | - Eduardo Aluicio-Sarduy
- Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, 53705, United States
| | - Kaelyn V Becker
- Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, 53705, United States
| | - Darren M Driscoll
- Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee, 37831, United States
| | - Nidhi Girish
- Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, PA, 15260
| | - Megan E Simms
- Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee, 37831, United States
| | - Vilmos Kertesz
- Biosciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee, 37831, United States
| | - Frankie D White
- Radioisotope Science and Technology Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee, 37831, United States
| | - Eszter Boros
- Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin, 53705, United States
| | - Alexander S Ivanov
- Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee, 37831, United States
| | - Jonathan W Engle
- Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, 53705, United States
- Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin, 53705, United States
| | - Nikki A Thiele
- Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee, 37831, United States
| |
Collapse
|
2
|
Sieber A, Spiess S, Rassy WY, Schild D, Rieß T, Singh S, Jain R, Schönberger N, Lederer F, Kremser K, Guebitz GM. Fundamentals of bio-based technologies for selective metal recovery from bio-leachates and liquid waste streams. Front Bioeng Biotechnol 2025; 12:1528992. [PMID: 39850509 PMCID: PMC11755047 DOI: 10.3389/fbioe.2024.1528992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2024] [Accepted: 12/24/2024] [Indexed: 01/25/2025] Open
Abstract
The number of metal-containing waste streams resulting from electronic end-of life products, metallurgical by-products, and mine tailings to name but a few, is increasing worldwide. In recent decades, the potential to exploit these waste streams as valuable secondary resources to meet the high demand of critical and economically important raw materials has become more prominent. In this review, fundamental principles of bio-based metal recovery technologies are discussed focusing on microbial metabolism-dependent and metabolism-independent mechanisms as sustainable alternatives to conventional chemical metal recovery methods. In contrast to previous reviews which have partially addressed this topic, a special focus will be given on how fundamental principles of bio-based recovery technologies can influence the selectivity and specificity of metal recovery. While conventional methods for metal recovery show benefits in terms of economic affordability, bio-based recovery technologies offer advantages in terms of efficiency and environmentally friendliness. Modifications and adaptations in the processes of biosorption, bioaccumulation and bioelectrochemical systems are highlighted, further emphasizing the application of metal-binding peptides and siderophores to increase selectivity in the recovery of metals. Single metal solutions or mixtures with a low complexity have been the focus of previous studies and reviews, but this does not reflect the nature of complex industrial effluents. Therefore, key challenges that arise when dealing with complex polymetallic solutions are addressed and the focus is set on optimizing bio-based technologies to recover metals efficiently and selectively from bio-leachates or liquid waste streams.
Collapse
Affiliation(s)
| | | | - Wadih Y. Rassy
- Department of Science and Technology, Institute of Biotechnology, IMC University of Applied Sciences, Krems, Austria
- Faculty of Technical Chemistry, TU Wien, Vienna, Austria
| | - Dominik Schild
- Department of Science and Technology, Institute of Biotechnology, IMC University of Applied Sciences, Krems, Austria
| | - Thomas Rieß
- Department of Science and Technology, Institute of Biotechnology, IMC University of Applied Sciences, Krems, Austria
| | - Shalini Singh
- Helmholtz-Zentrum Dresden-Rossendorf, Helmholtz Institute Freiberg for Resource Technology, Biotechnology Department, Dresden, Germany
| | - Rohan Jain
- Helmholtz-Zentrum Dresden-Rossendorf, Helmholtz Institute Freiberg for Resource Technology, Biotechnology Department, Dresden, Germany
| | - Nora Schönberger
- Helmholtz-Zentrum Dresden-Rossendorf, Helmholtz Institute Freiberg for Resource Technology, Biotechnology Department, Dresden, Germany
| | - Franziska Lederer
- Helmholtz-Zentrum Dresden-Rossendorf, Helmholtz Institute Freiberg for Resource Technology, Biotechnology Department, Dresden, Germany
| | - Klemens Kremser
- Department of Agrobiotechnology, IFA-Tulln, Institute of Environmental Biotechnology, BOKU University of Natural Resources and Life Sciences Vienna, Tulln an der Donau, Austria
- Austrian Centre of Industrial Biotechnology, Tulln an der Donau, Austria
| | - Georg M. Guebitz
- Department of Agrobiotechnology, IFA-Tulln, Institute of Environmental Biotechnology, BOKU University of Natural Resources and Life Sciences Vienna, Tulln an der Donau, Austria
- Austrian Centre of Industrial Biotechnology, Tulln an der Donau, Austria
| |
Collapse
|
3
|
Zobnin VA, Zhuikov BL, Vasiliev AN, Polnyakov GA. Gas-chemical approach to 225Ac/ 213Bi radionuclide generator for medical application. Appl Radiat Isot 2024; 215:111581. [PMID: 39536600 DOI: 10.1016/j.apradiso.2024.111581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2024] [Revised: 10/15/2024] [Accepted: 11/05/2024] [Indexed: 11/16/2024]
Abstract
The article presents a novel gas-chemical approach for 225Ac/213Bi generators, which provides effective separation of 213Bi from parent 225Ac. The main problem with the generators of high activity is the radiation stability of sorbents, which is not substantial in this gas-chemical method of separation, where only radiationally stable inorganic materials are used. The approach includes heating at high temperature (about 900-1000 °C) 225Ac sample deposited on a backing material (Nb, quartz glass, stainless steel) in hydrogen-containing inert gas flow. Actinium is non-volatile in these conditions, while Bi sublimes and is deposited on a catcher-foil along a temperature gradient. Niobium was found to be the best of the used material for both the starting backing and catcher-foil. The effective activation energy of carrier-free amount of Bi-sublimation from Nb-backing as 102 ± 9 kJ/mol has been calculated, and standard enthalpy of desorption of Bi on Nb from thermochromatographic data has been evaluated as 269 ± 13 kJ/mol 213Bi may be recovered for the consequent preparation of radiopharmaceuticals by washing from the catcher-foil surface. The gas-chemical method has been demonstrated to be a promising approach for 225Ac/213Bi generators for its application in targeted alpha therapy.
Collapse
Affiliation(s)
- Vladislav A Zobnin
- Institute for Nuclear Research of Russian Academy of Sciences, Moscow, Troitsk, 117312, Russia.
| | - Boris L Zhuikov
- Institute for Nuclear Research of Russian Academy of Sciences, Moscow, Troitsk, 117312, Russia
| | - Aleksandr N Vasiliev
- Institute for Nuclear Research of Russian Academy of Sciences, Moscow, Troitsk, 117312, Russia; Shenzhen MSU-BIT University, Faculty of Materials Science, Shenzhen, 518172, China
| | - Gleb A Polnyakov
- Institute for Nuclear Research of Russian Academy of Sciences, Moscow, Troitsk, 117312, Russia
| |
Collapse
|
4
|
Wood JL, Ghosh S, Houston ZH, Fletcher NL, Humphries J, Mardon K, Akhter DT, Tieu W, Ivashkevich A, Wheatcroft MP, Thurecht KJ, Codd R. A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements. Chem Sci 2024; 15:11748-11760. [PMID: 39092114 PMCID: PMC11290327 DOI: 10.1039/d4sc02851a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2024] [Accepted: 05/21/2024] [Indexed: 08/04/2024] Open
Abstract
A covalent adduct of DFOB and DOTA separated by a l-lysine residue (DFOB-l-Lys-N 6-DOTA) exhibited remarkable regioselective metal binding, with {1H}-13C NMR spectral shifts supporting Zr(iv) coordinating to the DFOB unit, and Lu(iii) coordinating to the DOTA unit. This first-in-class, dual-chelator theranostic design could enable the use of imaging-therapy radiometal pairs of different elements, such as 89Zr for positron emission tomography (PET) imaging and 177Lu for low-energy β--particle radiation therapy. DFOB-l-Lys-N 6-DOTA was elaborated with an amine-terminated polyethylene glycol extender unit (PEG4) to give DFOB-N 2-(PEG4)-l-Lys-N 6-DOTA (compound D2) to enable installation of a phenyl-isothiocyanate group (Ph-NCS) for subsequent monoclonal antibody (mAb) conjugation (mAb = HuJ591). D2-mAb was radiolabeled with 89Zr or 177Lu to produce [89Zr]Zr-D2-mAb or [177Lu]Lu-D2-mAb, respectively, and in vivo PET/CT imaging and in vivo/ex vivo biodistribution properties measured with the matched controls [89Zr]Zr-DFOB-mAb or [177Lu]Lu-DOTA-mAb in a murine LNCaP prostate tumour xenograft model. The 89Zr-immuno-PET imaging function of [89Zr]Zr-D2-mAb and [89Zr]Zr-DFOB-mAb showed no significant difference in tumour accumulation at 48 or 120 h post injection. [89Zr]Zr-D2-mAb and [177Lu]Lu-D2-mAb showed similar ex vivo biodistribution properties at 120 h post-injection. Tumour uptake of [177Lu]Lu-D2-mAb shown by SPECT/CT imaging at 48 h and 120 h post-injection supported the therapeutic function of D2, which was corroborated by similar therapeutic efficacy between [177Lu]Lu-D2-mAb and [177Lu]Lu-DOTA-mAb, both showing a sustained reduction in tumour volume (>80% over 65 d) compared to vehicle. The work identifies D2 as a trifunctional chelator that could expand capabilities in mixed-element radiometal theranostics to improve dosimetry and the clinical outcomes of molecularly targeted radiation.
Collapse
Affiliation(s)
- James L Wood
- The University of Sydney, School of Medical Sciences New South Wales 2006 Australia
- Centre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane Queensland 4072 Australia
| | - Saikat Ghosh
- Centre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane Queensland 4072 Australia
| | - Zachary H Houston
- Centre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane Queensland 4072 Australia
| | - Nicholas L Fletcher
- Centre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane Queensland 4072 Australia
| | - James Humphries
- Centre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane Queensland 4072 Australia
| | - Karine Mardon
- Centre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane Queensland 4072 Australia
| | - Dewan T Akhter
- Centre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane Queensland 4072 Australia
| | - William Tieu
- Molecular Imaging and Therapy Research Unit (MITRU), South Australian Health and Medical Research Institute (SAHMRI) Adelaide Australia
| | | | | | - Kristofer J Thurecht
- Centre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane Queensland 4072 Australia
| | - Rachel Codd
- The University of Sydney, School of Medical Sciences New South Wales 2006 Australia
| |
Collapse
|
5
|
George KJH, Borjian S, Cross MC, Hicks JW, Schaffer P, Kovacs MS. Expanding the PET radioisotope universe utilizing solid targets on small medical cyclotrons. RSC Adv 2021; 11:31098-31123. [PMID: 35498914 PMCID: PMC9041346 DOI: 10.1039/d1ra04480j] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Accepted: 08/25/2021] [Indexed: 12/17/2022] Open
Abstract
Molecular imaging with medical radioisotopes enables the minimally-invasive monitoring of aberrant biochemical, cellular and tissue-level processes in living subjects. The approach requires the administration of radiotracers composed of radioisotopes attached to bioactive molecules, the pairing of which considers several aspects of the radioisotope in addition to the biological behavior of the targeting molecule to which it is attached. With the advent of modern cellular and biochemical techniques, there has been a virtual explosion in potential disease recognition antigens as well as targeting moieties, which has subsequently opened new applications for a host of emerging radioisotopes with well-matched properties. Additionally, the global radioisotope production landscape has changed rapidly, with reactor-based production and its long-defined, large-scale centralized manufacturing and distribution paradigm shifting to include the manufacture and distribution of many radioisotopes via a worldwide fleet of cyclotrons now in operation. Cyclotron-based radioisotope production has become more prevalent given the commercial availability of instruments, coupled with the introduction of new target hardware, process automation and target manufacturing methods. These advances enable sustained, higher-power irradiation of solid targets that allow hospital-based radiopharmacies to produce a suite of radioisotopes that drive research, clinical trials, and ultimately clinical care. Over the years, several different radioisotopes have been investigated and/or selected for radiolabeling due to favorable decay characteristics (i.e. a suitable half-life, high probability of positron decay, etc.), well-elucidated chemistry, and a feasible production framework. However, longer-lived radioisotopes have surged in popularity given recent regulatory approvals and incorporation of radiopharmaceuticals into patient management within the medical community. This review focuses on the applications, nuclear properties, and production and purification methods for some of the most frequently used/emerging positron-emitting, solid-target-produced radioisotopes that can be manufactured using small-to-medium size cyclotrons (≤24 MeV).
Collapse
Affiliation(s)
- K J H George
- Lawson Health Research Institute 268 Grosvenor Street London ON N6A 4V2 Canada
- Medical Biophysics, Western University 1151 Richmond Street N. London ON N6A 5C1 Canada
| | - S Borjian
- ARTMS 301-4475 Wayburn Drive Burnaby BC V5G 4X4 Canada
| | - M C Cross
- ARTMS 301-4475 Wayburn Drive Burnaby BC V5G 4X4 Canada
| | - J W Hicks
- Lawson Health Research Institute 268 Grosvenor Street London ON N6A 4V2 Canada
- Medical Biophysics, Western University 1151 Richmond Street N. London ON N6A 5C1 Canada
| | - P Schaffer
- Life Sciences, TRIUMF 4004 Wesbrook Mall Vancouver BC V6T 2A3 Canada
- ARTMS 301-4475 Wayburn Drive Burnaby BC V5G 4X4 Canada
- Radiology, University of British Columbia 2775 Laurel St Vancouver BC V5Z 1M9 Canada
- Chemistry, Simon Fraser University 8888 University Dr Burnaby BC V5A 1S6 Canada
| | - M S Kovacs
- Lawson Health Research Institute 268 Grosvenor Street London ON N6A 4V2 Canada
- Medical Biophysics, Western University 1151 Richmond Street N. London ON N6A 5C1 Canada
- Medical Imaging, Western University 1151 Richmond Street N. London ON N6A 5C1 Canada
| |
Collapse
|
6
|
Choudhury D, Naskar N, Lahiri S. Distribution of different no-carrier-added radionuclides in Pb and Bi fractions after separation of bulk components of lead bismuth eutectic. J Radioanal Nucl Chem 2021. [DOI: 10.1007/s10967-021-07748-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
7
|
Chomet M, Schreurs M, Bolijn MJ, Verlaan M, Beaino W, Brown K, Poot AJ, Windhorst AD, Gill H, Marik J, Williams S, Cowell J, Gasser G, Mindt TL, van Dongen GAMS, Vugts DJ. Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET. Eur J Nucl Med Mol Imaging 2020; 48:694-707. [PMID: 32889615 PMCID: PMC8036225 DOI: 10.1007/s00259-020-05002-7] [Citation(s) in RCA: 58] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2020] [Accepted: 08/13/2020] [Indexed: 12/19/2022]
Abstract
Purpose Almost all radiolabellings of antibodies with 89Zr currently employ the hexadentate chelator desferrioxamine (DFO). However, DFO can lead to unwanted uptake of 89Zr in bones due to instability of the resulting metal complex. DFO*-NCS and the squaramide ester of DFO, DFOSq, are novel analogues that gave more stable 89Zr complexes than DFO in pilot experiments. Here, we directly compare these linker-chelator systems to identify optimal immuno-PET reagents. Methods Cetuximab, trastuzumab and B12 (non-binding control antibody) were labelled with 89Zr via DFO*-NCS, DFOSq, DFO-NCS or DFO*Sq. Stability in vitro was compared at 37 °C in serum (7 days), in formulation solution (24 h ± chelator challenges) and in vivo with N87 and A431 tumour-bearing mice. Finally, to demonstrate the practical benefit of more stable complexation for the accurate detection of bone metastases, [89Zr]Zr-DFO*-NCS and [89Zr]Zr-DFO-NCS-labelled trastuzumab and B12 were evaluated in a bone metastasis mouse model where BT-474 breast cancer cells were injected intratibially. Results [89Zr]Zr-DFO*-NCS-trastuzumab and [89Zr]Zr-DFO*Sq-trastuzumab showed excellent stability in vitro, superior to their [89Zr]Zr-DFO counterparts under all conditions. While tumour uptake was similar for all conjugates, bone uptake was lower for DFO* conjugates. Lower bone uptake for DFO* conjugates was confirmed using a second xenograft model: A431 combined with cetuximab. Finally, in the intratibial BT-474 bone metastasis model, the DFO* conjugates provided superior detection of tumour-specific signal over the DFO conjugates. Conclusion DFO*-mAb conjugates provide lower bone uptake than their DFO analogues; thus, DFO* is a superior candidate for preclinical and clinical 89Zr-immuno-PET. Electronic supplementary material The online version of this article (10.1007/s00259-020-05002-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Marion Chomet
- Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117 Amsterdam, The Netherlands
| | - Maxime Schreurs
- Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117 Amsterdam, The Netherlands
| | - Maria J. Bolijn
- Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117 Amsterdam, The Netherlands
| | - Mariska Verlaan
- Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117 Amsterdam, The Netherlands
| | - Wissam Beaino
- Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117 Amsterdam, The Netherlands
| | - Kari Brown
- Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117 Amsterdam, The Netherlands
| | - Alex J. Poot
- Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117 Amsterdam, The Netherlands
| | - Albert D. Windhorst
- Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117 Amsterdam, The Netherlands
| | - Herman Gill
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080 USA
| | - Jan Marik
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080 USA
| | - Simon Williams
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080 USA
| | - Joseph Cowell
- Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, Chimie ParisTech, PSL University, CNRS, Paris, France
| | - Gilles Gasser
- Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, Chimie ParisTech, PSL University, CNRS, Paris, France
| | - Thomas L. Mindt
- Ludwig Boltzmann Institute for Applied Diagnostics, General Hospital Vienna (AKH), Vienna, Austria
| | - Guus A. M. S van Dongen
- Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117 Amsterdam, The Netherlands
| | - Danielle J. Vugts
- Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117 Amsterdam, The Netherlands
| |
Collapse
|
8
|
Cultivation dependent formation of siderophores by Gordonia rubripertincta CWB2. Microbiol Res 2020; 238:126481. [DOI: 10.1016/j.micres.2020.126481] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Revised: 03/31/2020] [Accepted: 04/15/2020] [Indexed: 11/24/2022]
|
9
|
Dewulf J, Adhikari K, Vangestel C, Wyngaert TVD, Elvas F. Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders-An Update. Cancers (Basel) 2020; 12:E1868. [PMID: 32664521 PMCID: PMC7408676 DOI: 10.3390/cancers12071868] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2020] [Revised: 07/06/2020] [Accepted: 07/10/2020] [Indexed: 01/12/2023] Open
Abstract
Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are molecular imaging strategies that typically use radioactively labeled ligands to selectively visualize molecular targets. The nanomolar sensitivity of PET and SPECT combined with the high specificity and affinity of monoclonal antibodies have shown great potential in oncology imaging. Over the past decades a wide range of radio-isotopes have been developed into immuno-SPECT/PET imaging agents, made possible by novel conjugation strategies (e.g., site-specific labeling, click chemistry) and optimization and development of novel radiochemistry procedures. In addition, new strategies such as pretargeting and the use of antibody fragments have entered the field of immuno-PET/SPECT expanding the range of imaging applications. Non-invasive imaging techniques revealing tumor antigen biodistribution, expression and heterogeneity have the potential to contribute to disease diagnosis, therapy selection, patient stratification and therapy response prediction achieving personalized treatments for each patient and therefore assisting in clinical decision making.
Collapse
Affiliation(s)
- Jonatan Dewulf
- Molecular Imaging Center Antwerp, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium; (J.D.); (C.V.); (T.V.D.W.)
- Department of Nuclear Medicine, Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem, Belgium
| | - Karuna Adhikari
- Faculty of Pharmaceutical Biomedical and Veterinary Sciences, Medicinal Chemistry, University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium;
| | - Christel Vangestel
- Molecular Imaging Center Antwerp, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium; (J.D.); (C.V.); (T.V.D.W.)
- Department of Nuclear Medicine, Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem, Belgium
| | - Tim Van Den Wyngaert
- Molecular Imaging Center Antwerp, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium; (J.D.); (C.V.); (T.V.D.W.)
- Department of Nuclear Medicine, Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem, Belgium
| | - Filipe Elvas
- Molecular Imaging Center Antwerp, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium; (J.D.); (C.V.); (T.V.D.W.)
- Department of Nuclear Medicine, Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem, Belgium
| |
Collapse
|
10
|
de la Fuente A, Radchenko V, Tsotakos T, Tsoukalas C, Paravatou-Petsotas M, Harris AL, Köster U, Rösch F, Bouziotis P. Conjugation, labelling and in vitro/in vivo assessment of an anti-VEGF monoclonal antibody labelled with niobium isotopes. J Radioanal Nucl Chem 2018. [DOI: 10.1007/s10967-018-6314-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Abstract
Nuclear medicine is composed of two complementary areas, imaging and therapy. Positron emission tomography (PET) and single-photon imaging, including single-photon emission computed tomography (SPECT), comprise the imaging component of nuclear medicine. These areas are distinct in that they exploit different nuclear decay processes and also different imaging technologies. In PET, images are created from the 511 keV photons produced when the positron emitted by a radionuclide encounters an electron and is annihilated. In contrast, in single-photon imaging, images are created from the γ rays (and occasionally X-rays) directly emitted by the nucleus. Therapeutic nuclear medicine uses particulate radiation such as Auger or conversion electrons or β- or α particles. All three of these technologies are linked by the requirement that the radionuclide must be attached to a suitable vector that can deliver it to its target. It is imperative that the radionuclide remain attached to the vector before it is delivered to its target as well as after it reaches its target or else the resulting image (or therapeutic outcome) will not reflect the biological process of interest. Radiochemistry is at the core of this process, and radiometals offer radiopharmaceutical chemists a tremendous range of options with which to accomplish these goals. They also offer a wide range of options in terms of radionuclide half-lives and emission properties, providing the ability to carefully match the decay properties with the desired outcome. This Review provides an overview of some of the ways this can be accomplished as well as several historical examples of some of the limitations of earlier metalloradiopharmaceuticals and the ways that new technologies, primarily related to radionuclide production, have provided solutions to these problems.
Collapse
Affiliation(s)
- Eszter Boros
- Department of Chemistry , Stony Brook University , Stony Brook , New York 11794 , United States
| | - Alan B Packard
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology , Boston Children's Hospital , Boston , Massachusetts 02115 , United States.,Harvard Medical School , Boston , Massachusetts 02115 , United States
| |
Collapse
|
12
|
Aluicio-Sarduy E, Ellison PA, Barnhart TE, Cai W, Nickles RJ, Engle JW. PET radiometals for antibody labeling. J Labelled Comp Radiopharm 2018; 61:636-651. [PMID: 29341227 PMCID: PMC6050152 DOI: 10.1002/jlcr.3607] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Revised: 12/29/2017] [Accepted: 01/05/2018] [Indexed: 02/06/2023]
Abstract
Recent advances in molecular characterization of tumors have made possible the emergence of new types of cancer therapies where traditional cytotoxic drugs and nonspecific chemotherapy can be complemented with targeted molecular therapies. One of the main revolutionary treatments is the use of monoclonal antibodies (mAbs) that selectively target the disseminated tumor cells while sparing normal tissues. mAbs and related therapeutics can be efficiently radiolabeled with a wide range of radionuclides to facilitate preclinical and clinical studies. Non-invasive molecular imaging techniques, such as Positron Emission Tomography (PET), using radiolabeled mAbs provide useful information on the whole-body distribution of the biomolecules, which may enable patient stratification, diagnosis, selection of targeted therapies, evaluation of treatment response, and prediction of dose limiting tissue and adverse effects. In addition, when mAbs are labeled with therapeutic radionuclides, the combination of immunological and radiobiological cytotoxicity may result in enhanced treatment efficacy. The pharmacokinetic profile of antibodies demands the use of long half-life isotopes for longitudinal scrutiny of mAb biodistribution and precludes the use of well-stablished short half-life isotopes. Herein, we review the most promising PET radiometals with chemical and physical characteristics that make the appealing for mAb labeling, highlighting those with theranostic radioisotopes.
Collapse
Affiliation(s)
| | - Paul A. Ellison
- University of Wisconsin-Madison, Department of Medical Physics, Madison, Wisconsin, USA
| | - Todd E. Barnhart
- University of Wisconsin-Madison, Department of Medical Physics, Madison, Wisconsin, USA
| | - Weibo Cai
- University of Wisconsin-Madison, Department of Medical Physics, Madison, Wisconsin, USA
- University of Wisconsin-Madison, Department of Radiology, Madison, Wisconsin, USA
- University of Wisconsin-Madison Carbone Cancer Center, Carbon Cancer Center, Madison, Wisconsin, USA
| | - Robert Jerry Nickles
- University of Wisconsin-Madison, Department of Medical Physics, Madison, Wisconsin, USA
| | - Jonathan W. Engle
- University of Wisconsin-Madison, Department of Medical Physics, Madison, Wisconsin, USA
- University of Wisconsin-Madison, Department of Radiology, Madison, Wisconsin, USA
| |
Collapse
|
13
|
Petrik M, Zhai C, Novy Z, Urbanek L, Haas H, Decristoforo C. In Vitro and In Vivo Comparison of Selected Ga-68 and Zr-89 Labelled Siderophores. Mol Imaging Biol 2017; 18:344-52. [PMID: 26424719 PMCID: PMC4870302 DOI: 10.1007/s11307-015-0897-6] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Purpose Some [68Ga]siderophores show promise in specific and sensitive imaging of infection. Here, we compare the in vitro and in vivo behaviour of selected Ga-68 and Zr-89 labelled siderophores. Procedures Radiolabelling was performed in HEPES or sodium acetate buffer systems. Radiochemical purity of labelled siderophores was determined using chromatography. Partition coefficients, in vitro stability and protein binding affinities were determined. Ex vivo biodistribution and animal imaging was studied in mice. Results Certain differences among studied siderophores were observed in labelling efficiency. Protein binding and stability tests showed highest stabilities and lowest protein binding affinities for Ga-68 and [89Zr]triacetylfusarinine C (TAFC). All studied Ga-68 and [89Zr]siderophores exhibited a similar biodistribution and pharmacokinetics in mice with the exception of [89Zr]ferrioxamine E (FOXE). Conclusions Zr-89 and [68Ga]siderophores showed analogous in vitro and in vivo behaviour. Tested [89Zr]siderophores could be applied for longitudinal positron emission tomography (PET) studies of fungal infections and especially TAFC for the development of novel bioconjugates. Electronic supplementary material The online version of this article (doi:10.1007/s11307-015-0897-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Milos Petrik
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 5, CZ-77900, Olomouc, Czech Republic.
| | - Chuangyan Zhai
- Clinical Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria
| | - Zbynek Novy
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 5, CZ-77900, Olomouc, Czech Republic
| | - Lubor Urbanek
- Laboratory of Growth Regulators, Centre of the Region Hana for Biotechnological and Agricultural Research, Institute of Experimental Botany AS CR & Palacky University, Olomouc, Czech Republic
| | - Hubertus Haas
- Division of Molecular Biology/Biocenter, Medical University Innsbruck, Innsbruck, Austria
| | - Clemens Decristoforo
- Clinical Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria
| |
Collapse
|
14
|
Pandya DN, Bhatt N, Yuan H, Day CS, Ehrmann BM, Wright M, Bierbach U, Wadas TJ. Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. Chem Sci 2017; 8:2309-2314. [PMID: 28451334 PMCID: PMC5363373 DOI: 10.1039/c6sc04128k] [Citation(s) in RCA: 82] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Accepted: 12/12/2016] [Indexed: 11/21/2022] Open
Abstract
We report our initial investigations into the use of tetraazamacrocycles as zirconium-89 chelators. We describe the synthesis and complete characterization of several Zr tetraazamacrocycle complexes, and definitively describe the first crystal structure of zirconium 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (Zr-DOTA) using single crystal X-ray diffraction analysis. After evaluating several radioactive analogs, we found that 89Zr-DOTA is superior to 89Zr-DFO, the only 89Zr-complex to be used clinically in 89Zr-radiopharmaceutical applications. Finally, we provide a rationale for the unanticipated and extraordinary stability of these complexes in vitro and in vivo. These results may inform the development of safer and more robust immuno-PET agents for precision medicine applications.
Collapse
Affiliation(s)
- Darpan N Pandya
- Department of Cancer Biology , Wake Forest School of Medicine , Winston-Salem , NC 27157 , USA . ;
| | - Nikunj Bhatt
- Department of Cancer Biology , Wake Forest School of Medicine , Winston-Salem , NC 27157 , USA . ;
| | - Hong Yuan
- Department of Radiology , University of North Carolina at Chapel Hill , Chapel Hill , NC 27599 , USA
| | - Cynthia S Day
- Department of Chemistry , Wake Forest University , Winston-Salem , NC 27109 , USA
| | - Brandie M Ehrmann
- Department of Chemistry , University of North Carolina at Chapel Hill , Chapel Hill , NC 27599 , USA
| | - Marcus Wright
- Department of Chemistry , Wake Forest University , Winston-Salem , NC 27109 , USA
| | - Ulrich Bierbach
- Department of Chemistry , Wake Forest University , Winston-Salem , NC 27109 , USA
| | - Thaddeus J Wadas
- Department of Cancer Biology , Wake Forest School of Medicine , Winston-Salem , NC 27157 , USA . ;
| |
Collapse
|
15
|
Direct flow separation strategy, to isolate no-carrier-added 90Nb from irradiated Mo or Zr targets. RADIOCHIM ACTA 2016. [DOI: 10.1515/ract-2015-2543] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
90Nb has an intermediate half-life of 14.6 h, a high positron branching of 53% and optimal β
+ emission energy of only E
mean 0.35 MeV per decay. These favorable characteristics suggest it may be a potential candidate for application in immuno-PET. Our recent aim was to conduct studies on distribution coefficients for ZrIV and NbV in mixtures of HCl/H2O2 and HCl/oxalic acid for anion exchange resin (AG 1 × 8) and UTEVA resin to develop a “direct flow” separation strategy for 90Nb. The direct flow concept refers to a separation accomplished using a single eluent on multiple columns, effectively streamlining the separation process and increasing the time efficiency. Finally, we also demonstrated that this separation strategy is applicable to the production of the positron emitter 90Nb via the irradiation of molybdenum targets and isolation of 90Nb from the irradiated molybdenum target.
Collapse
|
16
|
Radchenko V, Bouziotis P, Tsotakos T, Paravatou-Petsotas M, la Fuente AD, Loudos G, Harris AL, Xanthopoulos S, Filosofov D, Hauser H, Eisenhut M, Ponsard B, Roesch F. Labeling and preliminary in vivo assessment of niobium-labeled radioactive species: A proof-of-concept study. Nucl Med Biol 2016; 43:280-7. [PMID: 27150030 DOI: 10.1016/j.nucmedbio.2016.02.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2015] [Revised: 01/15/2016] [Accepted: 02/04/2016] [Indexed: 10/22/2022]
Abstract
The application of radionuclide-labeled biomolecules such as monoclonal antibodies or antibody fragments for imaging purposes is called immunoscintigraphy. More specifically, when the nuclides used are positron emitters, such as zirconium-89, the technique is referred to as immuno-PET. Currently, there is an urgent need for radionuclides with a half-life which correlates well with the biological kinetics of the biomolecules under question and which can be attached to the proteins by robust labeling chemistry. (90)Nb is a promising candidate for in vivo immuno-PET, due its half-life of 14.6h and low β(+) energy of Emean=0.35MeV per decay. (95)Nb on the other hand, is a convenient alternative for longer-term ex vivo biodistribution studies, due to its longer half-life of (t½=35days) and its convenient, lower-cost production (reactor-based production). In this proof-of-principle work, the monoclonal antibody bevacizumab (Avastin(®)) was labeled with (95/90)Nb and in vitro and in vivo stability was evaluated in normal Swiss mice and in tumor-bearing SCID mice. Initial ex vivo experiments with (95)Nb-bevacizumab showed adequate tumor uptake, however at the same time high uptake in the liver, spleen and kidneys was observed. In order to investigate whether this behavior is due to instability of (⁎)Nb-bevacizumab or to the creation of other (⁎)Nb species in vivo, we performed biodistribution studies of (95)Nb-oxalate, (95)Nb-chloride and (95)Nb-Df. These potential metabolite species did not show any specific uptake, apart from bone accumulation for (95)Nb-oxalate and (95)Nb-chloride, which, interestingly, may serve as an "indicator" for the release of (90)Nb from labeled biomolecules. Concerning the initial uptake of (95)Nb-bevacizumab in non-tumor tissue, biodistribution of a higher specific activity radiolabeled antibody sample did show only negligible uptake in the liver, spleen, kidneys or bones. In-vivo imaging of a tumor-bearing SCID mouse after injection with (90)Nb-bevacizumab was acquired on an experimental small-animal PET camera, and indeed showed localization of the radiotracer in the tumor area. It is the first time that such results are described in the literature, and indicates promise of application of (90)Nb-labeled antibodies for the purposes of immuno-PET.
Collapse
Affiliation(s)
- Valery Radchenko
- Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany.
| | - Penelope Bouziotis
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, N.C.S.R. "Demokritos", Athens, Greece
| | - Theodoros Tsotakos
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, N.C.S.R. "Demokritos", Athens, Greece
| | - Mari Paravatou-Petsotas
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, N.C.S.R. "Demokritos", Athens, Greece
| | - Ana de la Fuente
- Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany
| | - George Loudos
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, N.C.S.R. "Demokritos", Athens, Greece; Department of Biomedical Engineering, Technological Educational Institute of Athens, Athens, Greece
| | - Adrian L Harris
- Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - Stavros Xanthopoulos
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, N.C.S.R. "Demokritos", Athens, Greece
| | - Dmitry Filosofov
- Dzhelepov Laboratory of Nuclear Problems, Joint Institute of Nuclear Research, Dubna, Moscow region, Russian Federation
| | - Harald Hauser
- Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
| | - Michael Eisenhut
- Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
| | - Bernard Ponsard
- Institute of Nuclear Materials Science, BR2 Reactor, Radioisotopes and NTD Silicon Production, Belgian Nuclear Research Centre, SCKCEN, Mol, Belgium
| | - Frank Roesch
- Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany.
| |
Collapse
|
17
|
Liu F, Zhu H, Li C, Lin X, Xiong C, Li C, Yang Z. Design and radio-synthesis of somatostatin receptors targeted 68Ga-DOTA-Benereotide for non-invasive PET imaging. J Radioanal Nucl Chem 2015. [DOI: 10.1007/s10967-015-4241-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|